Urogen Pharma (URGN) Short Interest Ratio & Short Volume $15.27 -0.14 (-0.91%) Closing price 04:00 PM EasternExtended Trading$15.18 -0.09 (-0.62%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Urogen Pharma Short Interest DataUrogen Pharma (URGN) has a short interest of 18.49 million shares, representing 42.26% of the float (the number of shares available for trading by the public). This marks a 201.63% increase in short interest from the previous month. The short interest ratio (days to cover) is 3.1, indicating that it would take 3.1 days of the average trading volume of 1.10 million shares to cover all short positions.Current Short Interest18,490,000 sharesPrevious Short Interest6,130,000 sharesChange Vs. Previous Month+201.63%Dollar Volume Sold Short$253.31 millionShort Interest Ratio3.1 Days to CoverLast Record DateJune 30, 2025Outstanding Shares46,200,000 sharesShort Percent of Float42.26%Today's Trading Volume1,201,133 sharesAverage Trading Volume1,101,348 sharesToday's Volume Vs. Average109% Short Selling Urogen Pharma? Sign up to receive the latest short interest report for Urogen Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartURGN Short Interest Over TimeURGN Days to Cover Over TimeURGN Percentage of Float Shorted Over Time Urogen Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/202518,490,000 shares $253.31 million +201.6%42.3%3.1 $13.70 6/15/20256,130,000 shares $73.74 million +56.4%14.0%2.3 $12.03 5/31/20253,920,000 shares $15.84 million -29.9%17.6%2.3 $4.04 5/15/20255,590,000 shares $55.06 million +11.4%25.1%5.4 $9.85 4/30/20255,020,000 shares $58.43 million -0.8%N/A10 $11.64 4/15/20255,060,000 shares $54.40 million -10.4%22.7%12.2 $10.75 3/31/20255,650,000 shares $62.49 million -8.1%25.4%14.2 $11.06 3/15/20256,150,000 shares $68.08 million +0.5%27.6%15.5 $11.07 2/28/20256,120,000 shares $57.90 million -1.1%27.5%15.7 $9.46 2/15/20256,190,000 shares $66.67 million +0.5%27.8%16.3 $10.77 Get the Latest News and Ratings for URGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Urogen Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/20256,160,000 shares $67.82 million +2.8%N/A15.5 $11.01 1/15/20255,990,000 shares $62.24 million +2.7%N/A14.2 $10.39 12/31/20245,830,000 shares $62.09 million +0.3%N/A10.8 $10.65 12/15/20245,810,000 shares $65.94 million +0.7%N/A11.1 $11.35 11/30/20245,770,000 shares $73.28 million -10.4%N/A10.2 $12.70 11/15/20246,440,000 shares $72.06 million -2.4%N/A11.1 $11.19 10/31/20246,600,000 shares $80.92 million +1.7%N/A11 $12.26 10/15/20246,490,000 shares $79.57 million -8.2%N/A11.3 $12.26 9/30/20247,070,000 shares $89.79 million +11.0%N/A13.6 $12.70 9/15/20246,370,000 shares $83.57 million -1.1%N/A12.3 $13.12 8/31/20246,440,000 shares $89.58 million -0.8%N/A9.1 $13.91 8/15/20246,490,000 shares $100.53 million +6.4%N/A9.5 $15.49 7/31/20246,100,000 shares $100.35 million +3.9%N/A9.6 $16.45 7/15/20245,870,000 shares $105.19 million -7.4%N/A9.5 $17.92 6/30/20246,340,000 shares $106.39 million +12.8%N/A10.5 $16.78 6/15/20245,620,000 shares $107.90 million +6.8%N/A9.8 $19.20 5/31/20245,260,000 shares $69.96 million +17.7%N/A15.5 $13.30 5/15/20244,470,000 shares $61.60 million +0.9%N/A13.7 $13.78 4/30/20244,430,000 shares $61.22 million +5.5%N/A12.7 $13.82 4/15/20244,200,000 shares $63.42 million +0.2%N/A11.5 $15.10 3/31/20244,190,000 shares $62.85 million -1.4%N/A12.6 $15.00 3/15/20244,250,000 shares $61.46 million +8.1%N/A12.4 $14.46 2/29/20243,930,000 shares $72.04 million -2.0%N/A12.7 $18.33 2/15/20244,010,000 shares $75.39 million +23.0%N/A13.2 $18.80 1/31/20243,260,000 shares $51.18 million -3.8%N/A11 $15.70 1/15/20243,390,000 shares $49.46 million -4.5%N/A12.9 $14.59 12/31/20233,550,000 shares $53.25 million +15.6%N/A13.5 $15.00 12/15/20233,070,000 shares $46.05 million +5.1%N/A11.3 $15.00 11/30/20232,920,000 shares $38.51 million +3.2%N/A12.4 $13.19 11/15/20232,830,000 shares $32.77 million +23.6%N/A11.4 $11.58Critical AI announcement set to ignite AI 2.0 (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 10/31/20232,290,000 shares $25.67 million +39.6%N/A7.9 $11.21 10/15/20231,640,000 shares $21.48 million +14.7%N/A2.6 $13.10 9/30/20231,430,000 shares $20.03 million +10.9%N/A2.3 $14.01 9/15/20231,290,000 shares $20.52 million -8.5%N/A2.1 $15.91 8/31/20231,410,000 shares $24.65 million -15.1%N/A2.2 $17.48 8/15/20231,660,000 shares $37.12 million +5.7%N/A2.7 $22.36 7/31/20231,570,000 shares $34.01 million +55.5%N/A2.8 $21.66 7/15/20231,010,000 shares $9.28 million +11.1%5.1%4 $9.19 6/30/2023909,100 shares $9.41 million +38.5%4.6%3.8 $10.35 6/15/2023656,300 shares $8.07 million -23.0%3.3%2.7 $12.29 5/31/2023852,100 shares $8.44 million -9.8%4.3%4.6 $9.90 5/15/2023944,700 shares $11.16 million +29.3%4.8%5.4 $11.81 4/30/2023730,500 shares $8.47 million -1.8%3.7%4.3 $11.59 4/15/2023743,700 shares $7.16 million +16.3%3.8%5.8 $9.63 3/31/2023639,500 shares $5.91 million +2.3%3.3%5.6 $9.24 3/15/2023625,300 shares $6.02 million +5.5%3.3%6.3 $9.63 2/28/2023592,900 shares $6.11 million +2.8%3.1%6.7 $10.30 2/15/2023576,700 shares $5.29 million +1.2%3.0%6.4 $9.17 1/31/2023569,700 shares $5.92 million +0.0%3.0%6.6 $10.39 1/15/2023569,600 shares $4.88 million -15.2%2.9%7.7 $8.56 12/30/2022671,700 shares $5.96 million -0.2%3.5%8.9 $8.87 12/15/2022673,000 shares $5.32 million +0.1%3.5%10.2 $7.91 11/30/2022672,600 shares $5.76 million -1.0%3.5%10.3 $8.57 11/15/2022679,700 shares $6.17 million -9.5%3.5%10.5 $9.08 10/31/2022751,100 shares $8.90 million -31.7%3.9%13 $11.85 10/15/20221,100,000 shares $12.65 million -20.3%5.8%19.5 $11.50 9/30/20221,380,000 shares $11.48 million -3.5%7.2%25.6 $8.32 9/15/20221,430,000 shares $13.46 million +1.4%7.5%15 $9.41 8/31/20221,410,000 shares $10.50 million -3.4%7.3%13 $7.45 8/15/20221,460,000 shares $12.64 million -0.7%7.6%10.3 $8.66 7/31/20221,470,000 shares $11.52 million -3.3%7.7%8.9 $7.84 7/15/20221,520,000 shares $13.77 million -10.6%7.9%8.4 $9.06 6/30/20221,700,000 shares $13.92 million -22.0%8.9%8.7 $8.19 6/15/20222,180,000 shares $14.72 million -10.7%11.4%10.6 $6.75 5/31/20222,440,000 shares $12.98 million +3.4%12.7%14.6 $5.32 5/15/20222,360,000 shares $14.04 million +3.5%12.3%15.8 $5.95 4/30/20222,280,000 shares $16.10 million +10.1%11.9%17 $7.06 4/15/20222,070,000 shares $16.21 million +4.6%10.8%15.7 $7.83 3/31/20221,980,000 shares $17.25 million -10.0%10.4%14.9 $8.71 3/15/20222,200,000 shares $18.55 million -0.5%11.6%16.7 $8.43 2/28/20222,210,000 shares $13.26 million +11.1%11.7%15.8 $6.00 2/15/20221,990,000 shares $14.23 million No Change10.5%14.5 $7.15 1/31/20221,990,000 shares $15.36 million +7.6%10.5%12.8 $7.72 1/15/20221,850,000 shares $15.71 million +2.2%9.8%12.2 $8.49 12/31/20211,810,000 shares $17.21 million -4.2%9.5%13.8 $9.51 12/15/20211,890,000 shares $19.18 million +3.9%9.9%16.3 $10.15 11/30/20211,820,000 shares $22.00 million +11.0%9.6%17.9 $12.09 11/15/20211,640,000 shares $24.17 million -6.3%8.6%16.8 $14.74 10/29/20211,750,000 shares $30.10 million -0.6%9.2%22.4 $17.20 10/15/20211,760,000 shares $29.96 million -4.9%9.3%20.8 $17.02Critical AI announcement set to ignite AI 2.0 (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 9/30/20211,850,000 shares $31.12 million -10.2%9.8%16.5 $16.82 9/15/20212,060,000 shares $31.37 million -6.8%10.9%16.1 $15.23 8/31/20212,210,000 shares $38.94 million -0.5%11.7%16.3 $17.62 8/13/20212,220,000 shares $33.59 million +7.8%11.7%16.1 $15.13 7/30/20212,060,000 shares $31.93 million -1.4%10.9%13.8 $15.50 7/15/20212,090,000 shares $32.19 million -1.9%11.1%14.8 $15.40 6/30/20212,130,000 shares $32.53 million -6.2%11.3%16.1 $15.27 6/15/20212,270,000 shares $38.79 million -7.4%12.0%17.4 $17.09 5/28/20212,450,000 shares $43.17 million +5.2%13.0%16.2 $17.62 5/14/20212,330,000 shares $35.84 million -0.4%12.3%13 $15.38 4/30/20212,340,000 shares $47.20 million -1.3%12.4%12.9 $20.17 4/15/20212,370,000 shares $41.78 million +1.7%12.5%12 $17.63 3/31/20212,330,000 shares $43.15 million -4.9%12.3%11.2 $18.52 3/15/20212,450,000 shares $48.00 million -11.2%12.9%11.1 $19.59 2/26/20212,760,000 shares $55.89 million +1.5%14.7%13.6 $20.25 2/12/20212,720,000 shares $70.94 million +3.8%14.5%14.8 $26.08 1/29/20212,620,000 shares $58.61 million -0.8%13.9%14.6 $22.37 1/15/20212,640,000 shares $55.26 million -1.9%14.0%15.3 $20.93 12/31/20202,690,000 shares $48.66 million +8.9%14.3%17.4 $18.09 12/15/20202,470,000 shares $45.97 million -9.5%13.1%17.9 $18.61 11/30/20202,730,000 shares $55.97 million +2.6%14.4%21.2 $20.50 10/30/20203,010,000 shares $69.20 million -3.8%16.0%20.1 $22.99 10/15/20203,130,000 shares $70.77 million -1.6%16.6%20.5 $22.61 9/30/20203,180,000 shares $61.34 million -0.6%16.9%20.5 $19.29 9/15/20203,200,000 shares $70.43 million +2.9%17.0%20.1 $22.01 8/31/20203,110,000 shares $78.03 million -0.6%16.5%19.7 $25.09 8/14/20203,130,000 shares $71.83 million +2.3%16.6%21 $22.95 7/31/20203,060,000 shares $67.60 million +2.3%17.0%18.9 $22.09 URGN Short Interest - Frequently Asked Questions What is Urogen Pharma's current short interest? Short interest is the volume of Urogen Pharma shares that have been sold short but have not yet been closed out or covered. As of June 30th, investors have sold 18,490,000 shares of URGN short. 42.26% of Urogen Pharma's shares are currently sold short. Learn More on Urogen Pharma's current short interest. What is a good short interest ratio for Urogen Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. URGN shares currently have a short interest ratio of 3.0. Learn More on Urogen Pharma's short interest ratio. Which institutional investors are shorting Urogen Pharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Urogen Pharma: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Urogen Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 42.26% of Urogen Pharma's floating shares are currently sold short. Is Urogen Pharma's short interest increasing or decreasing? Urogen Pharma saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 18,490,000 shares, an increase of 201.6% from the previous total of 6,130,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Urogen Pharma's short interest compare to its competitors? 42.26% of Urogen Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Urogen Pharma: Arrowhead Pharmaceuticals, Inc. (9.55%), Bausch Health Cos Inc. (2.86%), NewAmsterdam Pharma Company N.V. (11.06%), Apellis Pharmaceuticals, Inc. (22.25%), Twist Bioscience Corporation (0.05%), Recursion Pharmaceuticals, Inc. (35.52%), Agios Pharmaceuticals, Inc. (6.83%), Denali Therapeutics Inc. (9.91%), Beam Therapeutics Inc. (24.82%), Kiniksa Pharmaceuticals International, plc (6.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Urogen Pharma stock? Short selling URGN is an investing strategy that aims to generate trading profit from Urogen Pharma as its price is falling. URGN shares are trading down $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Urogen Pharma? A short squeeze for Urogen Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of URGN, which in turn drives the price of the stock up even further. How often is Urogen Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including URGN, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Arrowhead Pharmaceuticals Short Interest Data Bausch Health Cos Short Interest Data NewAmsterdam Pharma Short Interest Data Apellis Pharmaceuticals Short Interest Data Twist Bioscience Short Interest Data Recursion Pharmaceuticals Short Interest Data Agios Pharmaceuticals Short Interest Data Denali Therapeutics Short Interest Data Beam Therapeutics Short Interest Data Kiniksa Pharmaceuticals International Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:URGN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
